Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

NxStage Medical Inc Issues Q3 2013 Guidance In Line With Analysts' Estimates; Reaffirms FY 2013 Guidance


Thursday, 25 Jul 2013 07:24am EDT 

NxStage Medical Inc announced that for the third quarter of 2013, the Company is forecasting revenues to be between $66.5 million and $68.0 million, and a net loss in the range of $4.5 million to $3.5 million, or $(0.07) to $(0.06) per share. The Company reaffirmed its top line revenue and net loss guidance for 2013. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $67.6 million and net loss of $3.6 million and EPS of $(0.06) for the third quarter of 2013; and revenue of $266.13 million and net loss of $14.53 million for fiscal 2013. 

Company Quote

13.17
-0.23 -1.72%
20 Aug 2014